[Future Prospects of Cancer Cachexia].

Area of Science:

• Oncology
• Metabolic Syndromes
• Geriatric Medicine

Background:

• Cancer cachexia (CC) is a complex syndrome characterized by anorexia and significant loss of skeletal muscle mass.
• The definition of CC was established in 2011, and the novel anti-CC drug anamorelin was approved in Japan in 2021, marking a new phase in treatment.
• While anamorelin improves appetite and lean body mass, it does not fully restore skeletal muscle function.

Purpose of the Study:

• To highlight the need for combined intervention therapies for cancer cachexia.
• To discuss the ongoing development and clinical trials of non-pharmacological interventions for CC.
• To outline future research directions in understanding CC mechanisms, biomarkers, and treatment efficacy.

Main Methods:

• Review of current literature on cancer cachexia.
• Analysis of the efficacy and limitations of anamorelin treatment.
• Identification of ongoing clinical trials for combined CC therapies.

Main Results:

• Anamorelin shows promise in managing appetite and lean body mass in CC patients.
• Skeletal muscle function restoration remains a challenge with anamorelin monotherapy.
• Combined nutrition and exercise interventions are being investigated as essential components of CC management.

Conclusions:

• Combined intervention therapy, integrating pharmacologic and non-pharmacologic approaches, is necessary for comprehensive cancer cachexia management.
• Further research is essential to elucidate CC mechanisms, identify biomarkers, and develop targeted therapies.
• Clinical trials in Japan and Europe are exploring novel treatment strategies for improving skeletal muscle function in CC patients.